<DOC>
	<DOCNO>NCT03101085</DOCNO>
	<brief_summary>By study researcher hope learn S-equol , compound act like estrogen body , cause increase mitochondrial activity . Researchers also hope determine safety tolerability therapeutic dose S-equol whether influence cognition .</brief_summary>
	<brief_title>S-Equol Alzheimer 's Disease 2 Trial</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Equol</mesh_term>
	<criteria>Have diagnosis Alzheimer 's Disease ( AD ) Have study partner close relationship participant attend study visit participant Do possess Alkylphenol ethoxylates 4 ( APOE4 ) variant APOE gene Speak English primary language Have medication change within past 30 day Reside nursing home dementia special care unit Have potentially confound , serious medical risk insulinrequiring diabetes , history cancer require chemotherapy radiation therapy intervention within past 5 year , recent cardiac event Have clinically significant abnormal safety laboratory value SEAD2 screen visit Have clinically significant abnormal finding vital sign measurement , physical neurological examination SEAD2 screen visit Use type systemic estrogen testosterone replacement therapy Has participate another clinical trial receive investigational drug investigational therapy within 30 day Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>